Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
MDGL(NASDAQ:MDGL) CONSHOHOCKEN, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 1, 2025 to 17 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
MDGLCONSHOHOCKEN, Pa., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2025 to 11 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
MDGLCONSHOHOCKEN, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the European Commission (EC) has granted conditional marketing authorization for Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis. Rezdiffra is now the first and only approved therapy in the European Union (EU) for the treatment of MASH.
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
MDGLCONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
MDGLCONSHOHOCKEN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 15, 2025 to 36 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2023 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Reported Saturday, Madrigal's Rezdiffra Shows Significant Two-Year Improvements In Liver Stiffness And Portal Hypertension Risk In MASH Cirrhosis Patients
MDGLUBS Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $458
MDGLB. Riley Securities Reiterates Buy on Madrigal Pharmaceuticals, Raises Price Target to $460
MDGLCanaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $420
MDGLMadrigal Pharmaceuticals Q1 EPS $(3.32) Beats $(3.61) Estimate, Sales $137.25M Beat $113.76M Estimate
MDGLUncovering Potential: Madrigal Pharmaceuticals's Earnings Preview
MDGLJMP Securities Reiterates Market Outperform on Madrigal Pharmaceuticals, Maintains $443 Price Target
MDGLMadrigal Pharmaceuticals' Founder Rebecca Taub, To Transition To Senior Scientific and Medical Advisor; David Soergel, Appointed Chief Medical Officer
MDGLCitigroup Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $469
MDGLHC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $405
MDGLMadrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
MDGLMadrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations.
Madrigal Pharmaceuticals Q4 2024 GAAP EPS $(2.71) Beats $(4.16) Estimate, Sales $103.22M Beat $98.56M Estimate. Cash And Equivalents Of $931.3M
MDGLMadrigal Reveals Two-Year Data From Compensated MASH Cirrhosis Arm Of MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit Of Rezdiffra (resmetirom) In Patients With Compensated MASH Cirrhosis
MDGLHC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $400
MDGLMadrigal Pharmaceuticals Reports Preliminary Q4 And FY2024 Rezdiffra (Resmetirom) Net Sales Of $100M-$103M And $177M-$180M, Respectively, With Preliminary Cash Balance Of Approximately $931M, And As Of Year-end 2024, More Than 11,800 Patients On Rezdiffra
MDGLJMP Securities Reiterates Market Outperform on Madrigal Pharmaceuticals, Maintains $427 Price Target
MDGLCantor Fitzgerald Reiterates Neutral on Madrigal Pharmaceuticals
MDGLWatching Madrigal Pharmaceuticals; Traders Circulate Unconfirmed Rumor From M&A Blog That The Co May Be Seeing Takeover Interest
MDGLB. Riley Securities Maintains Neutral on Madrigal Pharmaceuticals, Raises Price Target to $236
MDGLUBS Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $441
MDGLMadrigal Pharmaceuticals Q3 2024 GAAP EPS $(4.92) Beats $(6.92) Estimate, Sales $62.175M Beat $33.656M Estimate
MDGLHow To Attend Madrigal Pharmaceuticals Q1 2022 Earnings Conference Call
MDGLMadrigal Pharmaceuticals (NASDAQ:MDGL) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.
